ENDRA Life Sciences (NDRA) Stock Price, News & Analysis

Company Overview

ENDRA Life Sciences, Inc. (NASDAQ: NDRA) is a medical technology company developing noninvasive diagnostic tools for tissue characterization. The company’s lead technology is Thermo-Acoustic Enhanced Ultrasound (TAEUS), which is designed to enhance conventional ultrasound systems with additional information about tissue properties.

ENDRA is initially applying TAEUS to the assessment of liver disease, including the detection and measurement of liver fat associated with conditions such as nonalcoholic fatty liver disease. The technology is intended to work with existing ultrasound equipment and could provide clinicians with a more accessible alternative to certain imaging procedures that are more expensive, less widely available, or involve ionizing radiation.

Based in Ann Arbor, Michigan, ENDRA has focused its development activities on expanding the capabilities of ultrasound imaging for use in routine clinical settings. TAEUS remains an investigational technology, and its availability and permitted uses depend on regulatory authorization in the applicable market.

Key Stats

• Today's Range: $4.41 to $4.53
• 50-Day Range: $4.41 to $6.50
• 52-Week Range: $2.96 to $6.95
• Volume: 4,580 shs
• Average Volume: 9,671 shs
• Market Capitalization: $6.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.00
• Consensus Rating: Hold

ENDRA Life Sciences Stock Analysis - MarketRank™

ENDRA Life Sciences scored higher than 54% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

ENDRA Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

ENDRA Life Sciences has a consensus price target of $25.00, representing about 466.9% upside from its current price of $4.41.

Amount of Analyst Coverage

ENDRA Life Sciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ENDRA Life Sciences are expected to grow in the coming year, from ($4.11) to ($3.04) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ENDRA Life Sciences is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ENDRA Life Sciences is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ENDRA Life Sciences has a P/B Ratio of 2.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.72% of the float of ENDRA Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

ENDRA Life Sciences has a short interest ratio ("days to cover") of 1.97, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ENDRA Life Sciences has recently decreased by 3.37%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ENDRA Life Sciences does not currently pay a dividend.

Dividend Growth

ENDRA Life Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

ENDRA Life Sciences has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for ENDRA Life Sciences this week, compared to 2 articles on an average week.

MarketBeat Follows

4 people have added ENDRA Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ENDRA Life Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.00% of the stock of ENDRA Life Sciences is held by insiders.

Percentage Held by Institutions

1.19% of the stock of ENDRA Life Sciences is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 11/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:NDRA
• CIK: 1681682
• Web: www.endrainc.com
• Phone: (734) 335-0468
• Fax: N/A
• Employees: 11
• Year Founded: N/A

Price Target and Rating

• Average Price Target for ENDRA Life Sciences: $25.00
• High Price Target: $25.00
• Low Price Target: $25.00
• Potential Upside/Downside: +466.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.03 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -246.34%
• Return on Assets: -150.81%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.10
• Quick Ratio: 7.10

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.92 per share
• Price / Book: 2.30

Miscellaneous

• Outstanding Shares: 1,500,000
• Free Float: 1,350,000
• Market Cap: $6.62 million
• Optionable: Not Optionable
• Beta: -0.07